https://ir.pelthos.com/ https://ir.pelthos.com/news-events https://ir.pelthos.com/news-events/press-releases https://ir.pelthos.com/news-events/ir-calendar https://ir.pelthos.com/news-events/presentations https://ir.pelthos.com/news-events/email-alerts https://ir.pelthos.com/news-events/investor-tax-notices https://ir.pelthos.com/company-info https://ir.pelthos.com/company-info/contacts https://ir.pelthos.com/company-info/faq https://ir.pelthos.com/financial-info https://ir.pelthos.com/financial-info/financial-results https://ir.pelthos.com/financial-info/income-statement https://ir.pelthos.com/financial-info/balance-sheet https://ir.pelthos.com/financial-info/cash-flow https://ir.pelthos.com/stock-data/quote-chart https://ir.pelthos.com/stock-data/historical-data https://ir.pelthos.com/stock-data/analyst-coverage https://ir.pelthos.com/sec-filings https://ir.pelthos.com/sec-filings/all-sec-filings https://ir.pelthos.com/sec-filings/annual-reports https://ir.pelthos.com/sec-filings/quarterly-reports https://ir.pelthos.com/sec-filings/section-16-filings https://ir.pelthos.com/governance https://ir.pelthos.com/governance/board-committees https://ir.pelthos.com/governance/governance-documents https://ir.pelthos.com/news-events/press-releases/detail/54/pelthos-therapeutics-announces-first-patient-dosed-in-phase-1b2a-clinical-trial-of-ct2000-in-eye-pain 2026-03-31T08:30:01-04:00 https://ir.pelthos.com/news-events/press-releases/detail/53/pelthos-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results 2026-03-19T06:30:02-04:00 https://ir.pelthos.com/news-events/press-releases/detail/52/pelthos-therapeutics-to-present-at-38th-annual-roth-conference 2026-03-12T08:30:04-04:00 https://ir.pelthos.com/news-events/press-releases/detail/51/pelthos-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-19-2026 2026-03-09T08:30:02-04:00 https://ir.pelthos.com/news-events/press-releases/detail/50/pelthos-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference 2026-02-23T08:00:02-05:00 https://ir.pelthos.com/news-events/press-releases/detail/49/pelthos-therapeutics-secures-up-to-50-million-senior-secured-term-loan-facility-from-horizon-technology-finance 2026-01-13T08:30:04-05:00 https://ir.pelthos.com/news-events/press-releases/detail/48/pelthos-therapeutics-acquires-xeglyze-abametapir-topical-treatment-for-head-lice 2026-01-05T07:30:02-05:00 https://ir.pelthos.com/news-events/press-releases/detail/47/pelthos-therapeutics-expands-board-of-directors-with-the-appointment-of-andrew-einhorn 2025-12-23T17:57:13-05:00 https://ir.pelthos.com/news-events/press-releases/detail/46/pelthos-therapeutics-signs-major-pharmacy-benefit-manager-agreement-expanding-patient-access-to-zelsuvmi-berdazimer-topical-gel-10-3 2025-12-04T07:00:02-05:00 https://ir.pelthos.com/news-events/press-releases/detail/45/pelthos-therapeutics-to-present-at-the-piper-sandler-37th-annual-healthcare-conference 2025-12-02T08:00:48-05:00 https://ir.pelthos.com/news-events/press-releases/detail/44/pelthos-therapeutics-announces-third-quarter-fiscal-2025-financial-results 2025-11-13T06:45:03-05:00 https://ir.pelthos.com/news-events/press-releases/detail/43/pelthos-therapeutics-acquires-xepi-ozenoxacin-cream-1-and-announces-18-million-private-convertible-notes-financing 2025-11-07T08:00:02-05:00 https://ir.pelthos.com/news-events/press-releases/detail/42/pelthos-therapeutics-to-report-third-quarter-2025-financial-results-on-november-13-2025 2025-11-05T08:01:16-05:00 https://ir.pelthos.com/news-events/press-releases/detail/41/pelthos-therapeutics-launches-moms-against-molluscum-movement-to-unite-families-affected-by-molluscum-contagiosum 2025-10-09T08:00:17-04:00 https://ir.pelthos.com/news-events/press-releases/detail/40/pelthos-therapeutics-to-participate-in-upcoming-september-investor-conferences 2025-09-08T08:30:02-04:00 https://ir.pelthos.com/news-events/press-releases/detail/39/pelthos-therapeutics-to-participate-in-the-2025-wells-fargo-healthcare-conference 2025-09-02T08:00:20-04:00 https://ir.pelthos.com/news-events/press-releases/detail/38/pelthos-therapeutics-reports-second-quarter-2025-financial-results-for-legacy-operations-and-provides-business-update 2025-08-18T08:00:02-04:00 https://ir.pelthos.com/news-events/press-releases/detail/37/pelthos-therapeutics-launches-zelsuvmi-berdazimer-topical-gel-10-3-the-first-and-only-fda-approved-at-home-treatment-for-molluscum-contagiosum 2025-07-10T08:00:01-04:00 https://ir.pelthos.com/news-events/press-releases/detail/36/pelthos-therapeutics-completes-merger-with-channel-therapeutics-and-closes-50-1-million-private-placement 2025-07-02T07:00:08-04:00 https://ir.pelthos.com/news-events/press-releases/detail/35/channel-therapeutics-announces-reverse-common-stock-split-in-conjunction-with-the-close-of-the-merger-with-pelthos-therapeutics-and-concurrent-50-1-million-private-placement 2025-06-27T09:15:00-04:00 https://ir.pelthos.com/news-events/press-releases/detail/34/channel-therapeutics-announces-positive-efficacy-results-for-the-treatment-of-eye-pain-using-its-nav1-7-inhibitor-in-multiple-preclinical-in-vivo-models 2025-05-14T08:00:10-04:00 https://ir.pelthos.com/news-events/press-releases/detail/33/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules 2025-05-01T17:00:01-04:00 https://ir.pelthos.com/news-events/press-releases/detail/32/ligand-subsidiary-pelthos-therapeutics-to-combine-with-channel-therapeutics 2025-04-17T06:02:03-04:00 https://ir.pelthos.com/news-events/press-releases/detail/31/channel-therapeutics-highlights-differences-between-nav1-7-and-nav1-8-in-light-of-recent-clinical-data-on-suzetrigine 2024-12-20T09:00:05-05:00 https://ir.pelthos.com/news-events/press-releases/detail/30/channel-therapeutics-announces-positive-efficacy-data-for-a-depot-formulation-of-a-nav1-7-inhibitor-in-a-preclinical-in-vivo-nerve-block-model 2024-12-18T08:30:19-05:00 https://ir.pelthos.com/news-events/press-releases/detail/29/chromocell-announces-name-change-to-channel-therapeutics-corporation-and-provides-therapeutic-program-updates 2024-11-21T09:49:08-05:00 https://ir.pelthos.com/news-events/press-releases/detail/28/chromocell-announces-unveiling-of-injectable-depot-program-for-the-treatment-of-surgical-pain 2024-10-29T08:30:09-04:00 https://ir.pelthos.com/news-events/press-releases/detail/27/chromocell-to-present-at-upcoming-fall-investor-conferences 2024-10-28T08:02:31-04:00 https://ir.pelthos.com/news-events/press-releases/detail/26/chromocell-announces-amendment-to-stock-repurchase-plan 2024-10-24T08:45:01-04:00 https://ir.pelthos.com/news-events/press-releases/detail/25/chromocell-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference 2024-09-03T09:00:04-04:00 https://ir.pelthos.com/news-events/press-releases/detail/24/chromocell-announces-stock-repurchase-plan 2024-08-07T08:45:01-04:00 https://ir.pelthos.com/news-events/press-releases/detail/23/chromocell-to-participate-in-the-virtual-investor-lunch-break-series 2024-07-15T09:00:04-04:00 https://ir.pelthos.com/news-events/press-releases/detail/22/chromocell-to-present-at-alliance-global-partners-healthcare-company-showcase-on-tuesday-may-21-2024 2024-05-13T09:00:01-04:00 https://ir.pelthos.com/news-events/press-releases/detail/21/chromocell-issues-letter-to-stockholders-from-chief-executive-officer 2024-04-09T08:30:06-04:00 https://ir.pelthos.com/news-events/press-releases/detail/20/chromocell-announces-formal-launch-of-eye-pain-treatment-program-and-hiring-of-dr-simon-chandler 2024-03-21T08:30:02-04:00 https://ir.pelthos.com/news-events/press-releases/detail/19/chromocell-names-frank-knuettel-as-chief-executive-officer-removing-interim-status-held-since-july-2023 2024-03-18T10:00:04-04:00 https://ir.pelthos.com/news-events/press-releases/detail/18/chromocell-to-present-at-sidoti-virtual-investor-conference-march-13-14 2024-03-11T09:00:01-04:00 https://ir.pelthos.com/news-events/press-releases/detail/17/benuvia-operations-llc-and-chromocell-therapeutics-corp-announce-strategic-partnership-to-advance-healthcare-solutions 2024-02-27T08:00:17-05:00 https://ir.pelthos.com/news-events/press-releases/detail/16/chromocell-therapeutics-announces-closing-ofinitial-public-offering-for-gross-proceeds-of-6-6-million 2024-02-21T16:47:26-05:00 https://ir.pelthos.com/news-events/press-releases/detail/15/chromocell-therapeutics-announces-pricing-of-upsized-6-6-initial-public-offering 2024-02-16T08:00:01-05:00 https://ir.pelthos.com/news-events/ir-calendar/detail/20260323-38th-annual-roth-conference 2026-03-13T13:45:29-04:00 https://ir.pelthos.com/news-events/ir-calendar/detail/20260319-fourth-quarter-and-full-year-2025-financial-results-call 2026-03-09T15:59:12-04:00 https://ir.pelthos.com/news-events/ir-calendar/detail/20260226-oppenheimer-36th-annual-healthcare-life-sciences-conference 2026-02-23T08:07:36-05:00 https://ir.pelthos.com/news-events/ir-calendar/detail/20251113-third-quarter-2025-financial-results-call 2025-11-05T08:35:11-05:00 https://ir.pelthos.com/sec-filings/all-sec-filings/content/0001919246-26-000039/wk-form4a_1775079571.html 2026-04-01T17:40:13-04:00 https://ir.pelthos.com/sec-filings/all-sec-filings/content/0001919246-26-000040/wk-form4a_1775079720.html 2026-04-01T17:42:45-04:00 https://ir.pelthos.com/sec-filings/all-sec-filings/content/0001919246-26-000041/wk-form4a_1775079742.html 2026-04-01T17:42:56-04:00 https://ir.pelthos.com/sec-filings/all-sec-filings/content/0001919246-26-000042/wk-form4a_1775079764.html 2026-04-01T17:43:16-04:00 https://ir.pelthos.com/sec-filings/all-sec-filings/content/0001919246-26-000043/wk-form4a_1775079819.html 2026-04-01T17:44:18-04:00 https://ir.pelthos.com/sec-filings/all-sec-filings/content/0001919246-26-000044/wk-form4a_1775079846.html 2026-04-01T17:44:48-04:00 https://ir.pelthos.com/sec-filings/all-sec-filings/content/0001919246-26-000045/wk-form4a_1775079878.html 2026-04-01T17:45:18-04:00 https://ir.pelthos.com/sec-filings/all-sec-filings/content/0001919246-26-000046/wk-form4a_1775079918.html 2026-04-01T17:45:53-04:00 https://ir.pelthos.com/sec-filings/all-sec-filings/content/0001919246-26-000047/wk-form4a_1775079936.html 2026-04-01T17:46:20-04:00 https://ir.pelthos.com/sec-filings/all-sec-filings/content/0001919246-26-000013/pths-20251231.htm 2026-03-19T06:40:05-04:00 https://ir.pelthos.com/sec-filings/all-sec-filings/content/0001919246-26-000014/pths-20260319.htm 2026-03-19T06:40:35-04:00 https://ir.pelthos.com/sec-filings/all-sec-filings/content/0001193125-26-055097/primary_doc.html 2026-02-17T17:15:33-05:00 https://ir.pelthos.com/sec-filings/all-sec-filings/content/0001753926-26-000321/g085131_424.htm 2026-02-13T16:17:08-05:00 https://ir.pelthos.com/sec-filings/all-sec-filings/content/9999999995-26-000493/primary_doc.html 2026-02-10T06:05:24-05:00 https://ir.pelthos.com/sec-filings/all-sec-filings/content/0001753926-26-000273/primary_doc.html 2026-02-05T16:09:31-05:00 https://ir.pelthos.com/sec-filings/all-sec-filings/content/0001753926-26-000231/g085075_s3.htm 2026-02-02T16:47:18-05:00 https://ir.pelthos.com/news-events/presentations/detail/23197/q3-2025-investor-presentation 2025-07-30T00:00:00-04:00 https://ir.pelthos.com/news-events/presentations/detail/23232/investor-presentation 2026-03-19T00:00:00-04:00 https://ir.pelthos.com/privacy-policy https://ir.pelthos.com/disclaimer https://ir.pelthos.com/sitemap https://ir.pelthos.com/accessibility-statement